Known targets — ChEMBL curated mechanism
CYP11A1CYP11B1CYP11B2CYP17A1ERG11
The experimentally established mechanism targets of Levoketoconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 known ✓ | P05093 | 15/20 | 1.00 |
| ▸ | CYP11B1 known ✓ | P15538 | 14/20 | 1.00 |
| ▸ | CYP11B2 known ✓ | P19099 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 19/20 | 1.00 |
| ▸ | CYP21A2 | P08686 | 16/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 16/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | CYP27B1 | O15528 | 1/20 | 1.00 |
| ▸ | CYP26A1 | O43174 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levoketoconazole SCHEMBL29384825 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL13575830 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL29588034 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Ketoconazole SCHEMBL18258319 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Ketoconazole SCHEMBL8408 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL24312989 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL41473 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL8407 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL1517472 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL11213392 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638648-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7351737-B2 | 4-[(8-substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-YL-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity | ALLERGAN, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | CYP17A1 35/4885CYP11B1 9/4885CYP11B2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.